C Stock Price Today (September 2026) — Citigroup Inc. Analysis & Key Metrics 2026-09-04
Citigroup Inc. (C) is trading at $137.72, down 0.30% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Financial Services growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $154.50 (12.2% upside).
- Volatility remains elevated (21.34% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (15.50% YoY) alongside significant competitive pressures.
C Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Citigroup Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $30.82B
P/E Ratio
Forward P/E: 10.22
Revenue Growth
Year over Year
Analyst Target
+12.2% upside potential
Key Investor Questions About C
What investors need to know before buying
Based on current market data, C presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 61.61)
- Fundamentals say: Mixed signals (nuanced financial profile)
C's growth trajectory depends on its ability to expand within the Banks - Diversified sector while managing margin pressures.
- Future growth will depend on performance in core Banks - Diversified operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for C investors include debt exposure and competitive dynamics in the Banks - Diversified industry.
- $881.62B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Banks - Diversified.
52-Week Trading Range
Over the past year, C stock traded between $92.96 and $147.96—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 21.34% annualized volatility and β=1.32, the stock exhibits high sensitivity to market moves—making C suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Hikma Pharmaceuticals (LSE:HIK) Stock Fair Value Edges Higher After Bullish Analyst Targets
Price targets for Hikma Pharmaceuticals are currently clustered in the £1,870 to £2,100 range, which sits above the latest fair value estimate of £19.70. Analysts linking these higher targets to Hikma Pharmaceuticals point to confidence in execution and valuation, although they also flag sensitivity to assumptions that could work against the stock if conditions change. As you read on, you will see how to interpret this evolving narrative and what to watch as new research comes...
Hammerson (LSE:HMSO) Stock Gets Fair Value Bump As Analysts Lift Targets
Hammerson sits at the centre of a fresh round of price target moves, with a central Fair Value estimate now at £3.94 compared with £3.78 previously. Recent research has pushed targets into a range of 395 GBp to 454 GBp as analysts update their views on how the company’s revenue profile and earnings power might justify higher or more cautious valuations. As you read on, you will see how to interpret these shifts and track the evolving Hammerson story in your own portfolio decisions. Analyst...
Citigroup (C) Stock May Be 31% Undervalued After Record Revenue Quarter
Citigroup stock has delivered a very strong 3 year return, yet current valuation checks suggest the shares may still trade at a discount to what some intrinsic value models imply. For investors, the puzzle is how to weigh that past performance against signals that both the Excess Returns model and market multiples point to undervaluation. Citigroup has returned 271.9% over the past 3 years, which puts extra focus on whether the current price still leaves room relative to underlying earning...
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?
In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.
Market Chatter: Anthropic May Give Morgan Stanley, Goldman Sachs Key Roles in $2 Trillion IPO
Anthropic could give Morgan Stanley (MS) and Goldman Sachs (GS) key roles in handling its market deb
Citigroup delays Fed rate cut forecast to June 2027
The bank had previously expected cuts in October and December 2026 and January 2027, but a stronger-than-expected August jobs report changed its outlook
Citigroup Falls 1.1% as Its Rate-Cut Clock Jumps to 2027
The delayed easing cycle could protect interest income while making consumer credit increasingly expensive.
Citi Sees Strong Jobs Data Delaying Rate Cut Bets To 2027 — Next Week's Inflation Print The Real Barometer
Citigroup has officially abandoned its expectations for Federal Reserve interest rate cuts in 2026.
Anthropic Follows SpaceX's Playbook With a $15 Billion Revolver
Commitments run from $1.25 billion down to $750 million depending on rank
Northern Trust's NII Rises 11% in Q2: Can Momentum Persist in 2026?
NTRS' NII rises 11% y/y in Q2, with lower funding costs and balance-sheet trends supporting momentum as management lifts 2026 growth guidance.
Explore More Analysis for C
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Citigroup Inc.
Citigroup Inc. (C) is currently trading at $137.72. The RSI (14-day) is at 61.6, indicating neutral territory. Wall Street analysts have a consensus "Hold" recommendation. The mean analyst price target of $154.50 implies 12.2% upside from current levels. Volatility is moderate at 21.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Citigroup Inc. (C): The trailing P/E ratio is 14.84, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 10.22, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.72, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 1.20. Price-to-Sales is 2.83. Valuation should be compared to Banks - Diversified industry peers for context, as different sectors trade at different multiples.
Based on 20 analysts covering C, the consensus price target is $154.50. This represents a 12.2% upside from the current price of $137.72. The range spans from a low target of $129.00 to a high target of $176.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Citigroup Inc. (C) pays a dividend with a current yield of approximately 1.95%. The annualized dividend rate is $2.40 per share. The payout ratio is 25.9%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-08-03T00:00:00.000Z.
Key risks for Citigroup Inc. (C) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Banks - Diversified sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Citigroup Inc.'s (C) current debt and financial health profile: Total debt stands at $881.62B. The company holds $1.10T in cash and equivalents.